The malignancy rates in these two randomised controlled clinical trials do not support a view that metformin offers any particular protection against malignancy compared with rosiglitazone. However, they do not refute the possibility of a difference compared with sulfonylureas.
No takes yet. Share an insight, caveat, or question.
Home et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: